-
European Radiology: Dual-energy CT provides better imaging predictive markers for patients with metastatic renal cell carcinoma
Time of Update: 2022-11-25
Subsequently, the patient showed a complete response, did not progress the disease, and is still alive; Follow-up: more than 21 monthsThis study shows that the early reduction of DL-CT-derived ΔIC (combined) and ΔZeffective (combined) can be used as an independent imaging predictor of favorable prognosis in patients with mRCC, which provides an imaging reference for the formulation of clinical personalized treatment plan.
-
Heavy release of Professor Cheng Ying: Septinib Chinese data injects a "booster" into RET fusion-positive NSCLC patients
Time of Update: 2022-11-15
In recent years, a series of results based on the global phase I/II LIBRETTO-001 STUDY HAS BROUGHT HOPE TO PATIENTS WITH RET FUSION. Breakthrough therapy, accelerated approval, the world's first appro
-
Small microorganisms, how to open a new breakthrough in triple-negative breast cancer immunotherapy?
Time of Update: 2022-11-15
Professor Shao Zhimin proposed three key clinical problems and their solutions: (1) limited effective population for treatment: analysis of breast cancer microenvironment characteristics to identify sensitive populations and key immune molecules; (2) Low efficacy of monotherapy: explore the mechanism of immune escape and find precise combined immunity strategies; (3) Insufficient clinical transformation of basic research: carry out immunotherapy clinical trials to promote the clinical transformation of new targets.
-
Technological breakthrough! CAR-T pioneer: 90% of cancers are expected to be treated by "herpes virus + CAR-T"!
Time of Update: 2022-11-15
Candel Therapeutics: HSV vectors remove barriers to CAR-T treatment of solid tumorsCandel Therapeutics, in collaboration with Carl June, is a clinical-stage biopharmaceutical company developing novel viral immunotherapies, Viral immunotherapies focused on helping patients fight cancer by eliciting systemic anti-tumor immune responses (Figure 5).
-
Elite soldiers, winning thousands of "cases" Donafenib improves the survival of patients with metastatic RAIR-DTC and provides better solutions for clinical practice
Time of Update: 2022-11-15
Changes in target lesions in patients during donafenib treatmentDonafenib treatment-related adverse reactions (TRAE) occur Case summaryThis case is FTC, and after total thyroidectomy of the left and right lobes, he was treated with radioactive iodine, and subsequent whole-body imaging did not show iodine uptake lesions.
-
Lin Aifu Research Group: Iron metabolism, iron death and long non-coding RNAs in cancer: known and unknown
Time of Update: 2022-11-15
Content introductionChinese Summary:Outline:Metabolic reprogramming is one of the hallmark events of tumors, through which cancer cells meet their own energy supply and unlimited proliferation.
Journal of Zhejiang University (English Edition) Series B: Biomedicine and Biotechnology,JZUS-B receives articles in life sciences, medicine, pharmacy, biochemistry, biotechnology and bioengineering, agronomy, ecology, and zoology.
-
Express treatment of non-small cell lung cancer, potential "first-in-class" therapy demonstrates anti-cancer activity
Time of Update: 2022-11-15
▲If you have any business needs, please long press to scan the QR code above, or▎WuXi AppTec content team editorSurface Oncology today announced its potential "first-in-class" antibody SRF388 as a monotherapy for patients with non-small cell lung cancer (NSCLC).
-
Neoadjuvant combined with radiotherapy double-fisted, some early breast cancer has been cured.
Time of Update: 2022-11-15
Neoadjuvant therapy has saved some patients with early-stage breast cancer from surgeryThis is a multicenter, single-arm Phase II clinical trial conducted at 7 centers in the United States, requiring patients over the age of 40 years with at most one lymph node metastasis and no distant organ metastases, and are classified as triple-negative breast cancer or HER2-positive breast cancer.
-
Research frontiers| Overweight or obese patients need to be aware of the complications after radical cystectomy
Time of Update: 2022-11-15
Studies have shown that obesity is a risk factor for poor prognosis of tumor patients, and foreign researchers have conducted a study to explain the association between body mass index (BMI) grouping and RC perioperative complications, and to determine the BMI threshold when the risk of complications is significantly reduced.
-
2022 ASH Quick Review Key clinical study data of Herkilenxel in the treatment of r/r B-ALL will be released soon, taking into account efficacy and safety
Time of Update: 2022-11-15
Patients with relapsed/refractory acute B-lymphoblastic leukemia (r/r B-ALL) have a short survival period, limited efficacy of existing drugs and poor access to new drugs in China, and new treatment m
-
List of key points of China's guidelines for esophageal cancer screening and early diagnosis and early treatment (2022, Beijing).
Time of Update: 2022-11-15
Esophageal cancer is one of the common malignant tumors of the digestive tract in China, which seriously threatens the life and health of Chinese residents. Screening, early diagnosis and early treatm
-
NRCO Release: Cancer is Getting Younger!
Time of Update: 2022-11-15
1038/s41571-022-00672-8Click "Read Original" to get more clinical dry goods*For medical professionals only, regardless of age, it should be taken seriouslyExecutive summaryOn September 6, 2022, researchers at Brigham and Women's Hospital published a study in Nature Reviews Clinical Oncology, revealing that the incidence of early-onset cancers (diagnosed before the age of 50) has increased dramatically around the world, including breast, colon, esophageal, kidney, liver and pancreatic cancers, and has risen sharply since around 1990.
-
Blood (IF=25) Lu Ying/Xia Li of Shanghai Jiao Tong University et al. revealed the mechanism of C1Q affecting extramedullary infiltration in acute myeloid leukemia
Time of Update: 2022-11-15
iNatureAcute myeloid leukemia (AML) is a fatal hematological malignancy that originates from the unlimited proliferation of immature progenitor cells, is characterized by intramedullary and extramedullary invasion, and has a 5-year overall survival rate of less than 30% after chemotherapy.
-
"Select TIL" cell therapy has been approved by the FDA for clinical trials, and is committed to breaking through the limitations of existing TIL products
Time of Update: 2022-11-15
544px;background-color: rgb(255, 255, 255);text-align: center;box-sizing: border-box !important;overflow-wrap: break-word !important;margin-bottom: 0px;">——List of recent popular events——November 8, HCP residual risk and controlOn November 9, nucleic acid drug process development new technologyNovember 3, 2022 /eMedClub News/--Turnstone Biologics, an immunotherapy company for solid tumors, announced that the FDA has approved its IND application for TIDAL therapy TIDAL-01 for the treatment of advanced solid tumors.
-
Does shortening the duration of radiotherapy have an effect on the efficacy of patients with early-stage breast cancer who are at high risk of recurrence?
Time of Update: 2022-11-15
Commentary first published: Medical pressWritten by the American Society for Radiation OncologyClick "Read Original" to get more clinical dry goodsOctober 24, 2022, a study at the annual meeting of the American Society of Radiation Oncology(ASTRO)showed that shortening the duration of radiation therapy did not affect the efficacy of patients with early-stage breast cancer who are at high risk of recurrence.
-
Professor Zhou Caicun talks about the key study of serplulimab being approved for lung squamous cell carcinoma indications
Time of Update: 2022-11-15
*For medical professionals onlyHeavy! Serplulimab ranks among the first-line treatments for lung squamous cell carcinoma!Based on the excellent efficacy and safety shown in ASTRUM-004 study, on Novemb
-
Treatment of neuroendocrine carcinoma of the gastrointestinal tract: cisplatin + irinotecan vs. cisplatin + etoposide
Time of Update: 2022-11-15
Current treatment options for extrapulmonary high-grade neuroendocrine carcinoma (NEC) are similar to those for small cell lung cancer, with case series showing similar efficacy for both cancers treated systemically.
-
Kong Delin, Hu Yongxian, Zhejiang University, et al.: It is safe and effective for patients with extramedullary recurrent lymphocytic leukemia after autologous CAR-T treatment to apply donor-derived CD19 CAR-T treatment again
Time of Update: 2022-11-15
Journal of Zhejiang University (English Edition) Series B: Biomedicine and Biotechnology,JZUS-B receives articles in life sciences, medicine, pharmacy, biochemistry, biotechnology and bioengineering, agronomy, ecology, and zoology.
-
Clinical necessity Re-radiotherapy for recurrent glioblastoma
Time of Update: 2022-11-15
Using stereotactic radiosurgery (SRS) or stereotactic radiation therapy (SRT), either hypofractionated or conventionally fractionated, several studies have shown a benefit in survival after re-irradiation in patients with relapsed GBM; However, questions remain to be answered about the effectiveness and toxicity of second course of radiation therapy.
-
The road is like a bridge, the walker has no boundaries - CSCO Autologous Transplantation Working Group 2022 Tour (Shanghai Station) was a complete success
Time of Update: 2022-11-15
On October 27, 2022, the "CSCO Autologous Transplantation Working Group 2022 Tour - Shanghai Station" hosted by the Chinese Society of Clinical Oncology (CSCO), CSCO Lymphoma Expert Committee, CSCO Le
